Actimab-A
Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)
Key Facts
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is focused on developing innovative, targeted radiotherapies to address unmet needs in oncology, particularly in hematologic malignancies and solid tumors. The company leverages its expertise with the Actinium-225 payload to create differentiated therapies, with its lead candidates in advanced clinical development. Strategic partnerships, such as the licensing deal with Immedica for Iomab-B in Europe, and collaborations with Astellas and AVEO, support its platform expansion and validate its technology.
View full company profileAbout Actinium Pharmaceuticals
Actinium Pharmaceuticals is focused on developing innovative, targeted radiotherapies to address unmet needs in oncology, particularly in hematologic malignancies and solid tumors. The company leverages its expertise with the Actinium-225 payload to create differentiated therapies, with its lead candidates in advanced clinical development. Strategic partnerships, such as the licensing deal with Immedica for Iomab-B in Europe, and collaborations with Astellas and AVEO, support its platform expansion and validate its technology.
View full company profileAbout Actinium Pharmaceuticals
Actinium Pharmaceuticals is focused on developing innovative, targeted radiotherapies to address unmet needs in oncology, particularly in hematologic malignancies and solid tumors. The company leverages its expertise with the Actinium-225 payload to create differentiated therapies, with its lead candidates in advanced clinical development. Strategic partnerships, such as the licensing deal with Immedica for Iomab-B in Europe, and collaborations with Astellas and AVEO, support its platform expansion and validate its technology.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| CLN-049 | Cullinan Therapeutics | Phase 1/2 |